iShares Genomics Immunology and Healthcare ETF (IDNA)
| Assets | $347.41M |
| NAV | $49.63 |
| Expense Ratio | 0.47% |
| PE Ratio | 27.74 |
| Shares Out | 7.00M |
| Dividend (ttm) | $0.09 |
| Dividend Yield | 0.18% |
| Ex-Dividend Date | Jun 10, 2021 |
| 1-Year Return | - |
| Volume | 88,324 |
| Open | 49.66 |
| Previous Close | 49.73 |
| Day's Range | 48.83 - 49.92 |
| 52-Week Low | 37.37 |
| 52-Week High | 55.55 |
| Beta | 0.78 |
| Holdings | 58 |
| Inception Date | Jun 11, 2019 |
About IDNA
The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
Top 10 Holdings
46.94% of assets| Name | Symbol | Weight |
|---|---|---|
| Moderna | MRNA | 6.21% |
| Intellia Therapeutics | NTLA | 5.49% |
| MERCK | MRK.DE | 5.02% |
| BioNTech SE | BNTX | 4.63% |
| EVOTEC | EVT.DE | 4.51% |
| Seagen | SGEN | 4.41% |
| GENMAB | GMAB.CO | 4.25% |
| Sarepta Therapeutics | SRPT | 4.19% |
| Regeneron Pharmaceuticals | REGN | 4.18% |
| BEIGENE LTD | 6160.HK | 4.03% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 10, 2021 | $0.05215 | Jun 16, 2021 |
| Dec 14, 2020 | $0.03621 | Dec 18, 2020 |
| Jun 15, 2020 | $0.08367 | Jun 19, 2020 |
| Dec 16, 2019 | $0.23706 | Dec 20, 2019 |
News
Take a Look at the Top-Performing Biotech ETFs YTD
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
Dig Deep: The Market Megatrends You Cannot Afford to Miss
As investors re-allocate in 2021, it is critical to look past the headlines to the overarching themes that will propel our economy into the future. Investors cannot afford to miss developments like digi...
Best Biotech ETFs for Q2 2021
The best biotech ETFs for Q2 2021 are ARKG, IDNA, and XBI.
Top-Performing Biotech ETFs Amid the COVID-19 Crisis
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Megatrends To Invest In Now: 3 Best ETF Picks
BlackRock has identified five big trends that are here to stay for the long haul. Investors can get exposure to these drivers via 17 iShares ETFs.
Go Beyond Trends: Healthcare Megatrends with the IDNA ETF
ETF investors looking ahead to 2021 tend to seek out current trends, but the megatrends run much deeper. These are the large-scale undercurrents that can disrupt a whole sector.
Best Biotech ETFs for Q1 2021
The best biotech ETFs for Q1 2021 are ARKG, BTEC, and IDNA.
ETF Strategies to Tap into Medical Breakthroughs, Healthcare Innovations
The election year and the coronavirus has highlighted the importance of an adaptive health industry that meets up with quickly changing times. Investors can also tap into this evolution in healthcare th...
Why You Should Invest in Genomics ETFs
Genomics ETFs have surged of late; here's why
Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data
Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.
Why Small-Cap Biotech ETFs Are Good Long-Term Bets
Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.
Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
Profit from the Genomics Market Momentum With These ETFs
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
3 ETFs For More Moderna Bets
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.
ETF Edge: Big boost for energy ETF
CNBC's Bob Pisani breaks down the biggest exchange-traded funds moves.
2 Biotechnology ETFs That Could Be Good For Diversification
While biotech stocks are often too risky for many investors, with the coronavirus raging and the race for a vaccine in play, taking a look at some ETFs that contain biotech stocks that are making stride...